

**TANTIA UNIVERSITY JOURNAL OF HOMOEOPATHY
AND MEDICAL SCIENCE
REVIEW ARTICLE****Volume 2 Issue 2(April-June 2019)****ISSN (E): 2581-8899
ISSN (P): 2581-978X****A Complete Review on Ginkgo Biloba****Dr. Siva Rami Reddy E.¹, Dr. Parveen Kumar²**¹Ph.D Scholar Tantia University, Sri Ganganagar,²Director Academic & Research, Tantia University, Sri Ganganagar**ABSTRACT**

The cerebrum and cerebellum (brain) is the stage for our emotional health. However, there is a developing assemblage of proof, and various significant voices are advocating the role of eating routine in the consideration and treatment of individuals with psychological health issues. Ginkgo biloba mother tincture has indicated valuable impact in treating impedances in memory, psychological speed, dementia, Alzheimer's dementia, cerebral stroke, vaso occlusive issue, and maturing. The reason for this review is to give the systems of activity, Pharmacological effects, Pharmacokinetics, pharmacological activity of Ginkgo biloba homoeopathy mother tincture.

Keywords: *Ginkgo biloba*, Pharmacological and phytochemical

Correseponding Author: Dr. Siva Rami Reddy E ¹Ph.D Scholar Tantia University, Sri Ganganagar

How to Cite: Reddy S R E, A Complete Review on Ginkgo Biloba. TU J .Homo & Medi Sci. 2019; 2(2):2-10

INTRODUCTION

The ginkgo biloba plant shape is apricot and fruits are yellow in colour¹. The ginkgo word is originally from Chinese (sankyo or yin kuo). The word meaning is silver fruit (or) lil apricot². The plant belong to family is ginkgoaceae, under classification of ginkgoatae. Ginkgo discovered by Englbert Kaemper in 1712. Ginkgo biloba is most common prescription by Indian homoeopathy physician. The most commonly used OTC (over the country) plant preparation in the United State of America³. United State of America has declared that ginkgo biloba for treatment for depression, memory deficiency, dementia, Alzheimer disease and other brain diseases⁴.

Today, almost more than 500 scientific papers now reporting Ginkgo's belongings make it the very much explored botanical medication accessible. With more than 10 million remedies

composed worldwide for Ginkgo biloba separate in 1989 alone, and a 140% development in the utilization of Ginkgo from 1997 to 1998, it is likely a plant drug your patients are utilizing or on the other hand considering⁵. There are a regularly expanding number of older individuals who experience the ill effects of feeble dementia and who need therapeutic consideration principally thus. Expectations that specific pharmaceuticals, alleged nootropic, insight improving, or anti dementia drugs, will demonstrate successful in the treatment of the dementia disorder are still countered by far reaching incredulity⁶. This is somewhat identified with reluctant and problematic methodological approaches in assessing the remedial adequacy of such medications. Moreover, moderately little verum placebo treatment contrasts of around 20%. All things considered, are typically

watched in concentrates with nootropic drugs. Moreover medication contender for the sign "decrepit dementia" don't demonstrate a typical system of activity⁷. Incredibly unique synthetic substances have been appeared to have an impact on probably a few parts of the unpredictable pathogenesis of essential degenerative dementia of the Alzheimer type (DAT). These substances work by improving dementia side effects and moderating down the movement of the sickness⁸.

Against this foundation, for the most part acknowledged guidelines in strategies for demonstrating the adequacy of nootropics have progressed toward becoming progressively increasingly significant. Inside a worldwide degree, a arrangement of logical advisory groups have arranged methodological proposals for the assessment of nootropic as well as anti dementia drugs⁹. These proposals incorporate - separated from clear meanings of incorporation finding and criteria and the evaluation of pathogenesis dependent on differential finding - the careful documentation of attendant ailments and associative prescription, the utilization of approved estimation techniques, the separation of essential and auxiliary factors, and an between gathering examination of predefined parameters and estimation time-focuses as corroborative investigation of predefined theories. The institutionalized ginkgo biloba uncommon concentrate Ginkgo leaf concentrate has as of now been examined in different clinical examinations¹⁰. These have demonstrated the positive impact of the concentrate - in creature tests also, human pharmacological examinations - on cerebral flow

and neuronal cell digestion ,hemorrhology and micro perfusion, the disposal of free radicals¹¹ .The muscarinic cholinergic framework . Also, the learning procedure¹². Studies have recommended its viability in ambiguously characterized impeded cerebrum works and appeared in vascular dementia of the alzheimers^{13,14}.

Botanical description:

Ginkgo biloba has a place with the plant group of Ginkgoaceae with equivalent words like pterophylla salisburiensis, salisburia adiantifolia and salisburia macrophylla¹⁵. The ginkgo plant, known to be among the most established living species on this world, has thrived in forests for more than 150 million and thus it is known as a living fossil. It is a famous tree with the male and female conceptive organs on discrete trees. They have a huge trunk with a circumference of around 7 m and a stature of around 30 m. Youthful trees are conifer like what's more, display stretching dimorphism¹⁶. Leaves grow in groups are light yellow in fall amid senescence¹⁷. The weathered leaves are very remarkably molded with two lobes and take after the maidenhair greenery in venation and shape¹⁸. The fertilization procedure includes the male microstrobilli bearing inexactly circulated sporangiophores containing microspores with male gametophytes and the female pendulous pairs of ovules borne on the shoots¹⁹. These trees start to imitate after around 20 by creating exposed seeds with an external plump layer²⁰. The external beefy layer of the fruit has an extensive measure of hexanoic acids and butanoic, which are dependable for the odor. Ginkgo biloba plants are available in china and North America²¹.



(A) Flower in stage



(B) Fruiting stage



(C) Mature Fruit Stage

(D) seeds of *ginkgo biloba***Figure 1. Different stages of *ginkgo biloba*****Ingredients of Ginkgo Biloba:**

Ginkgolides, Catechin, Sesquiterpenes, Flavonol and flavones glycosides, Ascorbic acid, P-hydroxybenzoic acid, diterpene lactones, iron based superoxide dismutase^{22,23}.

Common name of ginkgo biloba

Yinhsing (silver apricot – Japanese), Maidenhair tree, kew tree, salisburia adimifolia, Fossil tree, ginkgo, ginkyo, ginkgo folium²⁴.

Components of Ginkgo biloba

There are two principle pharmacologically dynamic groups of mixes present in the Ginkgo homoeopathy mother tincture. They are the terpenoids and flavonoids^{25,26}. Flavonoids, additionally called phenylchromones or phenylbenzopyrones, are a gathering of low molecular wt. substances that are broadly spread in the plant kingdom^{27,28}. Flavonoids present in the ginkgo mother tincture are flavones, tannins,

biflavones (bilobetol, 5 methoxybilobetol, isoginkgetin, ginkgetin), along with glycosides of quercitin & kaempferol attached to 3- rutinosides, 3- rhamnosides. These mixes are known to actmainly actmainly as antioxidants, enzyme suppressions^{29,30,31}.

Pharmacological effects of ginkgo biloba

Ginkgo leaf concentrate has demonstrated advantageous impacts in treating neurodegenerative ailments like cardiovascular disease, alzheimer's, stress, tinnitus, loss of memory, geriatric objections like giddiness, macular degeneration (age related) and schizophrenia³². These multifaceted exercises of the ginkgo mother tincture may work through different components of activity³³. The recommended components of the Ginkgo leaf concentrate are its cancer prevention agent impact, anti platelet activate factor (Anti PAF) movement for cerebral and cardio vascular illnesses, hindrance

of beta amyloid peptide (A) accumulation to lessen Alzheimer's movement, and diminished articulation of fringe benzodiazepine receptor for stress easing and incitement of endothelium

determined loosening up factor to improve blood flow³⁴.




Figure 2. Chemical structure of Ginkgo

Pharmacokinetics

Various investigations are distributed about the in vitro and in vivo pharmacological impacts and systems of ginkgo mother tincture and its segments³⁵. The broad learning about the pharmacokinetic qualities counting assimilation, discharge and digestion of the pharmacodynamic dynamic intensifies, the terpene trilactones and the flavonoids of Ginkgo biloba, permits an assessment and exchange of the pharmacological instruments³⁶. In 1986, Moreau alvconsidered the assimilation of a radiolabelled ¹⁴C concentrate arranged from ginkgo biloba mother tincture in rats^{37,38}. The pharmacokinetics of radiolabelled ginkgo mother tincture was trademark for a two compartment model, with an evident first request stage and a half-existence of around 4–5 h³⁹. Ingestion was in any event 60 % and explicit movement in blood crested after 1–5 h. At 3 h, the most elevated qualities for explicit radioactivity were estimated in the stomach and small digestive tract, demonstrating this might be the site of assimilation⁴⁰. Glandular, neuronal tissues and eyes demonstrated a high liking for the named

substance⁴¹. After oral organization, breathed out ¹⁴CO₂ represented around 38 % of the controlled portion after 72 h. After 72 h, 22 % was discharged in pee and 29 % in defecation^{42,43}.

In the course of recent years, the systematic strategies have appeared generous improvement as far as their lower point of confinement of identification and utmost of evaluation of terpene trilactones and flavonoids in natural lattices⁴⁴. Extraordinary scientific techniques [e.g. gas chromatography (GC)/mass spectrometry (MS), fluid chromatography (LC)/MS (electrospray ionization or barometrical weight synthetic ionization (APCI)) and LC/fluorescence finder have been distributed for the assurance of Ginkgo biloba constituents in the leaves, separates, pharmaceutical details and natural grids (for example plasma, cerebrum)⁴⁵. For GC investigation a derivatization venture with for instance BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) preceding investigation is fundamental, whereby silylated mixes are produced⁴⁶. A nitty gritty rundown of systematic techniques and attributes of

Ginkgo biloba constituents is distributed by van Beek and Montoro^{47,48}.

Pharmacological activity-

Cerebro vascular activity

A considerable amount of studies have tried the efficacy of ginkgo biloba mother tincture for improving status in those with cerebro vascular deficiency. In a double blind preliminary of ninety patients coordinated by Vesper and Hansgen et al over a multi week (12 week) course. Ginkgo was found to improve a couple of clinical parameters of measure including⁴⁹:

1) Patient consideration in assignments requiring snappy direction and readaptation. (2) For cerebral inadequacy (3) Changes in the patient's emotional exhibition (4) Changes in the patient's target conduct as seen by others. The after effects of past examinations demonstrated that ginkgo biloba mother tincture has fundamentally predominant impact than placebo treatment in all parameters estimated. The multicenter study did by Taillandier et al with longitudinal plan, performed under severe methodological conditions; discovered ginkgo biloba mother tincture was powerful against cerebral issue related with maturing in 166 patients⁵⁰. Results turned out to be measurably critical at three months, expanded amid the next months, and were harmonious with the in general clinical evaluation by the pro in control. Another study did by Grassel et al for twenty four week term with seventy two patients with cerebral insufficiency. The results indicated statistically better in short term memory following a month and a half, and learning rate following twenty four weeks. Ginkgo biloba mother tincture created improvement in parameters including: single side effects, total score of clinical indications, and worldwide adequacy⁵¹.

Memory impairment activity

While in a hybrid investigation of 18 old people, orally managed ginkgo biloba mother tincture was found to fundamentally improve the speed of data preparing in double coding tests (Allain et al)⁵², an investigation of 8 health females discovered contrasts between ginkgo biloba mother tincture and placebo treatment in just one of three strategies for assessment⁵³.

Alzheimers disease

A few studies propose that ginkgo biloba extract might be useful in treating Alzheimer's and dementia, with few if any reactions. A 1996 multicenter, double blind, placebo treatment controlled planned examination by Kanowski et al assessed one hundred fifty six patients with dementia of the Alzheimer's and multi infarct dementia who utilized either ginkgo biloba extract 120 milligram twice daily or placebo treatment for twenty four weeks⁵⁴. A multidimensional assessment approach utilizing target factors of Clinical Global Impressions (CGI) for psychopathological appraisal, Syndrome Kurztest(SKT) for appraisal of consideration and memory, and Nurnberger Modifies Beobachtungsskala (NAB) for evaluation of exercises of day by day life were utilized. Efficacy was characterized as reaction in in any event two of the three factors⁵⁵. Inside a moderately characterized reaction standard, 28% of the ginkgo biloba extract gathering reacted versus 10% in the placebo treatment gathering. Comparative impacts were noted with ginkgo biloba extract in the two types of dementia with a somewhat better reaction for those with alzheimers. 5 patients detailed minor symptoms of skin responses, G.I.T grievances, and HA⁵⁶. Ginkgo biloba extract likewise positioned prevalent in self-evaluated exercises of day by day living, improvement of the most unmistakable indication, and better in depression, exhibiting ginkgo biloba extract adequacy on conduct,

psychopathologic, and psychometric planes. Yao et al double blind placebo controlled study showed that ginkgo biloba mother tincture is inhibit the occurrence of A β from APP (beta amyloid precursor protein) in cases of the alzheimer's diseases.⁵⁷

Conclusion

Ginkgo biloba mother tincture is used very frequency in homoeopathy prescription for brain diseases. Different researches contemplated were completed to discover its phytomedicines and its viability under many conditions. Many research reports with respect to the utilization of ginkgo biloba mother tincture in vertigo, psychological problems, alzheimers disease, schizophrenia, tinnitus, memory improvement, asthma, venous and peripheral artery insufficiency. Before making educated clinical choices, homoeopathy physician should be clear about the indication, signs and symptoms, drug picture, dose, duration of drug action of ginkgo biloba.

References

1. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. *Altern Ther Health Med* 2001;7:70, 86, 88-90.
2. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extracts EGb 761 (Ginkgo). *Curr PharmDes* 2004;10:261-4.
3. Neldner KH. 2000. Complementary and alternative medicine. *Dermatol Clin* 18:189, 93,
4. Blumenthal M, editor. The complete German commission E Monographs: therapeutic guide to herbal medicines. Austin (TX): American Botanical Council; 1998.
5. Krauskopf R, Guinot P, Peetz HG. Long term on line EEG analyses demonstrating the pharmacodynamic effect of a defined Ginkgo biloba-extract. Karlsruhe. Germany: Beaufor-Schwabe International Report; 1983.
6. Izzo AA, Ernst E. 2001. Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs* 61:2163-75.
7. Landes P Market report: Whole Foods magazine's 2nd annual herb market survey or U.S. health food stores. *HerbalGram* 1997; 40:52.
8. Bruce J. Diamond et al, Review article: Ginkgo biloba Extract: Mechanisms and Clinical Indications, *Arch Phys Mad Rehabil* Vol81, May 2000, 668-678.
9. Kanowski, S., G. Ladurner, K. Maurer, W. D. Oswald, LI Stein: Outline for the evaluation of nootropic drugs. In: K. Maurer, P. Riederer, H. Beckmann (Eds.), *Alzheimer's disease, epidemiology, neuropathology, neurochemistry. and clinics* (1990) pp. 531 -543. Wien - New York: Springer-Verlag.
10. Leber, P: Guidelines for the clinical evaluation of antidementia drugs. 1st draft available from the FDA, November 8 (1990).
11. Heiss, W. D., K. Zeiler: *Medikamentöse Beeinflussung der Hindurchblutung (Drug influence on cerebral circulation)*. *Pharmakotherapie* 1 (1978) 137- 144.
12. Artmann, G., P. Michaelis, H. Schmid-Schonbein: Effect of ginkgo biloba extract 761 on microrheological parameters of red blood cells. *CUn. Hemorheol.* 9 (1989) 444.
13. Winter, E.: Effects of an extract of Ginkgo biloba on learning and memory in mice.

- Pharmacol. Biochem. and Behaviour 38 (1991) 109-114.
14. Taylor, j. E.: Liaison des neuromediateurs *h* leurs recepteurs dans le cerveau de rats. La Presse Medicale 15 (1986) 1491 – 1493.
 15. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. 2004. Polyphenols: food sources and bioavailability. AmJ Clin Nutr 79:727–47.
 16. McKenna DJ, Jones K, Hughes K. 2001. Efficacy, safety, and use of *Ginkgo biloba* in clinical and preclinical applications. Altern Ther HealthMed 7:70, 86, 88–90.
 17. Bilia AR. 2002. *Ginkgo biloba* L. Fitoterapia 73:276–9.
 18. Gertz HJ, Kiefer M. 2004. Review about *Ginkgo biloba* special extract EGb 761 (Ginkgo). Curr PharmDes 10:261–4.
 19. Goh LM, Barlow PJ. 2002. Antioxidant capacity in *Ginkgo biloba*. Food Res Int 35:815–20.
 20. Goh LML, Barlow PJ. 2004. Flavonoid recovery and stability from *Ginkgo biloba* subjected to a simulated digestion process. Food Chem 86:195–202..
 21. Mohutsky MA, Anderson GD, Miller JW, Elmer GW. 2006. *Ginkgo biloba*: evaluation of CYP2C9 drug interactions in vitro and in vivo. AmJ Ther 13:24–31.
 22. Krauskopf R, Guinot P, Peetz HG. Long term on line EEG analyses demonstrating the pharmacodynamic effect of a defined *Ginkgo biloba* extract. Karlsruhe. Germany: Beaufor-Schwabe International Report; 1983.
 23. Anonymous. *Ginkgo biloba* Extract (EGb 761) in perspective. Auckland 10, New Zealand: ADIS Press Ltd; 1990:1-20.
 24. Jacobs BP, Browner WS. *Ginkgo Biloba*: A Living fossil. American Journal of Medicine 2000; 108:341-2.
 25. Ahlemeyer B, Kriegelstein J. Neuroprotective effects of *Ginkgo biloba* extract. Cell Mol Life Sci 2003; 60(9): 1779-1792.
 26. Augustin S, Rimbach G, Augustin IL, Schliebs R, Wolfram S, Cermak R. Effect of a short and longterm treatment with *Ginkgo biloba* extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys 2009; 481(2): 177-1782.
 27. Birks J, Grimley Evans J. *Ginkgo biloba* for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2009; 1, CD003120.
 28. Ernst E, Pittler MH. *Ginkgo biloba* for vascular dementia and Alzheimer's disease: updated systematic review of double-blind, placebocontrolled, randomized trials. Perfusion 2005; 18:388–392.
 29. Bomhofi G, Maxion-Bergemann S, Matthiessen PF. External validity of clinical trials for treatment of dementia with *ginkgo biloba* extracts. Z Gerontol Geriatr 2008; 41(4): 298-312.
 30. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al. *Ginkgo biloba* for prevention of dementia: a randomized controlled trial. JAMA 2008; 300(19): 2253-2262.
 31. Schreiter Gasser U, Gasser T. A comparison of cholinesterase inhibitors and *ginkgo* extract in treatment of Alzheimer dementia. Fortschr Med Orig 2001; 119: 135-138.

32. Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract. *Pharmacol Res.* 2007; 56(6):493–502.
33. Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract in Alzheimer's disease: is there any evidence? *Curr Alzheimer Res.* 2007;4(3):253–62.
34. Leistner E, Drewke C. Ginkgo biloba and ginkgotoxin. *J Nat Prod.* 2009;73(1):86–92.
35. Moreau JP, Eck CR, McCabe J, et al. Absorption, distribution and elimination of a labelled extract of Ginkgo biloba leaves in the rat. *Presse Med.* 1986; 15(31):1458–61.
36. Kleijnen J, Knipschild P. Ginkgo biloba. *Lancet.* 1992; 340(8828):1136–9.
37. Fourtillan JB, Brisson AM, Girault J, et al. Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract. 1995; 50(2):137–44.
38. Mauri P, de Palma A, Pozzi F, et al. LC-MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts correlation with pharmacological activity. *J Pharm Biomed Anal.* 2006; 40(3):763–8.
39. Xie J, Ding C, Ge Q, et al. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC–MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2008; 864(1–2):87–94.
40. Rossi R, Basilico F, Rossoni G, et al. Liquid chromatography/ atmospheric pressure chemical ionization ion trap mass spectrometry of bilobalide in plasma and brain of rats after oral administration of its phospholipidic complex. *J Pharm Biomed Anal.* 2009; 50(2):224–7.
41. Ding S. Fingerprint profil of Ginkgo biloba nutritional supplement by LC/ESI–MS/MS. *Phytochemistry.* 2008; 69:1555–64.
42. Sora DI, Stefanescu V, David V, et al. Validation of an LC-MS/ MS assay of terpene trilactones in Ginkgo biloba extracts and pharmaceutical formulations through standard addition method. *J Pharm Biomed Anal.* 2009; 50(3):459–68.
43. Paulke A, Schubert-Zsilavecz M, Wurglics M. Determination of St. John's wort flavonoid-metabolites in rat brain through high performance liquid chromatography coupled with fluorescence detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006; 832(1):109–13.
44. Wang FM, Yao TW, Zeng S. Determination of quercetin and kaempferol in human urine after orally administrated tablet of Ginkgo biloba extract by HPLC. *J Pharm Biomed Anal.* 2003; 33(2):317–21.
45. Watson DG, Pitt AR. Analysis of flavonoids in tablets and urine by gas chromatography/mass spectrometry and liquid chromatography/ mass spectrometry. *Rapid Commun Mass Spectr.* 1998; 12(4):153–6.
46. Ding S, Dudley E, Chen L, et al. Determination of active components of Ginkgo biloba in human urine by capillary highperformance liquid chromatography/mass spectrometry with on line column-switching purification.

- Rapid Commun Mass Spectr. 2006; 20(24):3619–24.
47. Wang DL, Liang Y, Chen WD, et al. Identification of ginkgolide B metabolites in urine and rat liver cytochrome P450 enzymes responsible for their formation in vitro. *Acta Pharmacol Sin.* 2008; 29(3):376–84.
48. Lv H, Wang G, Wu X, et al. Transport characteristics of ginkgolide B by Caco-2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method. *Int J Pharm.* 2008; 351(1–2):31–5.
49. Drieu K. Preparation and definition of Ginkgo biloba extract. In: Funfgeld EW, ed. *Rokan (Ginkgo biloba): Recent Results in Pharmacology and Clinic.* Berlin: Springer-Verlag. 1988: 32-36.
50. Taillandier J, Ammar A, Rabourdin JP et al. Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter doubleblind drug vs. placebo study. *Presse Med.* 1986; 15:1583-1587.
51. Grasse E, Effect of Ginkgo-biloba extract on mental performance. Double blind study using computerized measurement conditions in patients with cerebral insufficiency. *Fortschr Med.* 1992; 110(5):73-76.
52. Allain et al. Effect of two doses of ginkgo biloba extract on the dual-coding test in elderly subjects. *Clin Ther.* 1993; 15:549-558.
53. Hindmarch I. Activity of Ginkgo biloba extract on short-term memory. *Presse Med*1986; 15:1592- 1594.
54. Fourtillan JB, et al. Pharmacokinetics of Bilobalide, Ginkgolide A and Binkgolide B in healthy volunteers following oral and intravenous administrations of Ginkgo biloba extract. *Therapie.* 1995; 50:137-144.
55. Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb in outpatients suffering from mild to moderate primary degeneratedementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatr.* 1996; 29:47-56.
56. Hasse J, Halama P, Horr R. Effectiveness of brief infusions with Ginkgo biloba Special Extract EGb in dementia of the vascular and Alzheimer type. *Z Gerontol Geriatr.* 2996; 29(4):302-309.
57. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract inhibits beta amyloid production by lowering free cholesterol levels. *J Nutr Biochem* 2004.15:749–56.

Conflict of Interest: None**Source of Support: Nil**

This work is licensed under a Creative Commons Attribution 4.0 International License